TMO

Thermo Fisher Scientific TMO is set to release second-quarter 2026 results on July 23, before the market opens. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $5.44, which surpassed the Zacks Consensus Estimate by 4.62%. The company’s earnings topped estimates in each of the trailing four quarters, the average surprise being 3.69%. The Zacks Consensus Estimate for revenues is pegged at $11.68 billion, indicating an increase of 7.6% from the year-ago reported figure. The consensus mark for the company’s EPS implies a 6.5% year-over-year rise to $5.71. The estimate has dropped 1 cent in the past 30 days. The segment’s performance is expected to have benefited from continued strength in the Bioproduction business, driven by healthy demand from the pharma and biotech customers. Thermo Fisher further enhanced its Bioproduction offerings through the acquisition of Solventum’s Filtration and Separation business, adding advanced filtration technologies and industrial filtration and membrane solutions. Integration of this business is likely to have continued during the quarter. A steady cadence of product launches is also expected to have supported the Life Sciences Solutions segment. Among its newer innovations, Thermo Fisher introduced the Gibco CTS Compleo Fill and Finish System to help address manual fill and finish challenges in cell therapy manufacturing. The company also launched an integrated platform to advance scalable cell therapy manufacturing and introduced the Gibco CHOvantage GS Cell Line Development (“CLD”) Kit to help biologics developers accelerate time to clinic while maintaining regulatory confidence and commercial scalability. Thermo Fisher’s new Applied Biosystems PowerFlex Thermal Cycler is designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. We expect all these developments to have positively boosted revenues in the second quarter of 2026. Per the Zacks Consensus Estimate, the Life Sciences Solutions revenues are expected to increase 9.6% year over year. The segment is likely to have continued to witness soft demand for instruments from academic and government customers in the United States and China. Tariffs and lower volumes may have also weighed on profitability. Despite this, Thermo Fisher’s strength in innovati...

Abbott Laboratories ABT is slated to report its second-quarter 2026 results on July 16, before the opening bell. The Zacks Consensus Estimate for the company’s second-quarter earnings per share (EPS) suggests 1.6% year-over-year growth to $1.28. The estimate has remained constant in the past 60 days. The consensus mark for second-quarter revenues currently stands at $12.48 billion, implying a 12% increase over the prior-year period. Image Source: Zacks Investment Research In the trailing four quarters, the company topped earnings estimates twice and broke even on two occasions, the average surprise being 0.42%. Image Source: Zacks Investment Research Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below. Earnings ESP: Abbott has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank:The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here. Within this segment, Abbott may have delivered mixed performance in the second quarter. Rapid and Molecular Diagnostics are likely to have continued to face reduced demand for respiratory virus testing. At the same time, steady demand for the Core Lab diagnostic tests may have been a tailwind, with strong performance across the United States, Europe and Latin America. Following the acquisition of Exact Sciences, Abbott added the Cancer Diagnostics business, expanding into one of the fastest-growing areas of healthcare. We assume the division to have favorably impacted the quarter’s results, driven by the Cologuard colorectal cancer (CRC) test momentum and contributions from the international markets. A positive development in the quarter was the American Cancer Society’s updated CRC screening guidelines, reaffirming Cologuard and Cologuard Plus as preferred non-invasive screening options for adults aged 45 and older who are at average risk. This is expected to have positively boosted adoption trends and revenues. The Zacks Consensus Estimate anticipates Diagnostics revenues to increase 41.6% year over year. The segment is expected to have maintained its growth momentum in key emerging markets, supported by favorable long-term hea...

WALTHAM, Mass., July 09, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on October 15, 2026, to shareholders of record as of September 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260709002023/en/ Contacts Media Contact Information:Sandy PoundThermo Fisher ScientificPhone: 781-622-1223E-mail: [email protected] Investor Contact Information:Rafael TejadaThermo Fisher ScientificPhone: 781-622-1356E-mail: [email protected]

ICON plc ICLR is facing a classic recovery-stock test. The valuation has compressed, bookings have improved and backlog is larger. The problem is that the earnings reset is not over. Investors still have to weigh better order flow against weaker 2026 expectations, margin pressure, control remediation and leverage. ICLR trades at roughly 16.9X forward 12-month earnings. That is below its five-year median of 18.1X and below the broader Zacks Medical sector and S&P 500 multiples in the same valuation snapshot. Image Source: Zacks Investment Research The discount gives the stock a value angle, but not a clean bargain label. The $164 price target sits below the quoted stock price of $173.06, suggesting the lower multiple does not fully offset the current risk profile. The bearish case starts with management’s outlook. ICON reaffirmed 2026 revenue guidance of $7.85 billion to $8.15 billion, below the $8.25 billion generated in 2025. Adjusted earnings per share guidance of $10.00 to $11.00 also trails 2025 adjusted earnings of $12.53 per share. That makes ICLR harder to frame as an immediate recovery story, because investors are still underwriting a year of lower sales and lower earnings. The turnaround case rests on better demand indicators. Net business wins totaled $2.88 billion in the first quarter of 2026, gross bookings reached $3.26 billion, cancellations were $383 million and net book-to-bill was 1.42X. Backlog rose 4% sequentially to $22.7 billion. Management also pointed to new partnerships, including a central labs partnership with a top-five pharma customer and a midsized pharma win that displaced an incumbent large contract research organization provider. The financial benefit is expected to be more relevant to 2027 than 2026, so backlog still needs to convert into margins and earnings. IQVIA Holdings Inc. IQV is a relevant peer because it also serves life sciences customers across research, development, data and technology. Thermo Fisher Scientific Inc. TMO, through its PPD clinical research business, gives investors another comparison point for competitive dynamics in contract research. Execution risk remains elevated because ICON is not dealing only with a demand cycle. The Audit Committee investigation found improper revenue adjustments tied to clinical trial services from the third quarter of 2023 through the fourth quarter of 2024, along with err...

WALTHAM, Mass., July 01, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2026 before the market opens on Thursday, July 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the "Investors" section of our website, www.thermofisher.com. You can access the conference call by dialing (833) 461-5787 within the U.S. or +1 (585) 542-9983 outside the U.S. The access code is 835035800. The earnings press release and related information can also be found in that section of our website, under the heading "Financials". A replay of the call will be available under "News, Events & Presentations" through Wednesday, October 21, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260701995913/en/ Contacts Media Contact Information:Sandy PoundPhone: 781-622-1223E-mail: [email protected] Website: www.thermofisher.com Investor Contact Information:Rafael TejadaPhone: 781-622-1356E-mail: [email protected]

Waltham, Massachusetts-based Thermo Fisher Scientific Inc. (TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. Valued at $190.7 billion by market cap, the company provides a portfolio of reagents, instruments, and consumables for research, drug development, and disease diagnosis, along with laboratory products and biopharma services. The leading scientific research services and products provider is expected to announce its fiscal second-quarter earnings for 2026 in the near term. Ahead of the event, analysts expect TMO to report a profit of $5.71 per share on a diluted basis, up 6.5% from $5.36 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. Memory Demand Sent Seagate Soaring — But This Stock Looks Even Better Nvidia Is Still a Bargain. Analysts See 57% Upside in NVDA Stock. McDonald's Corp Stock May Have Hit Bottom - Ways to Play MCD Stock Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the full year, analysts expect TMO to report EPS of $24.84, up 8.6% from $22.87 in fiscal 2025. Its EPS is expected to rise 9.4% year over year to $27.18 in fiscal 2027. TMO stock has outperformed the S&P 500 Index’s ($SPX) 19.9% gains over the past 52 weeks, with shares up 24% during this period. Similarly, it outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 20% returns over the same time frame. TMO beat expectations on bioproduction and clinical research strength, overcoming soft academic, government, and diagnostics demand. CEO Marc Casper called it a “very predictable” quarter, fueled by the $9 billion Clario deal and cost discipline. With pharma/biotech up mid-single digits and new tools like Glacios 3 Cryo-TEM rolling out, TMO hiked guidance but kept an inflation buffer as macro risks linger. Analysts’ consensus opinion on TMO stock is bullish, with a “Strong Buy” rating overall. Out of 26 analysts covering the stock, 20 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and five give a “Hold.” TMO’s average analyst price target is $593.24, indicating a potential upside of 17.1% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any...

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how research tools & consumables stocks fared in Q1, starting with Thermo Fisher (NYSE:TMO). The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts’ consensus estimates by 1.3% while next quarter’s revenue guidance was 2% above. Luckily, research tools & consumables stocks have performed well with share prices up 13% on average since the latest earnings results. With over 14,000 sales personnel and a portfolio spanning more than 2,500 technology manufacturers, Thermo Fisher Scientific (NYSE:TMO) provides scientific equipment, reagents, consumables, software, and laboratory services to pharmaceutical, biotech, academic, and healthcare customers worldwide. Thermo Fisher reported revenues of $11.01 billion, up 6.2% year on year. This print exceeded analysts’ expectations by 1.5%. Overall, it was a satisfactory quarter for the company with a beat of analysts’ EPS estimates but organic revenue in line with analysts’ estimates. Even though it had a relatively good quarter, the market seems discontent with the results. The stock is down 5.2% since...

ICON plc ICLR is moving through a credibility and earnings reset that is now as much about controls as it is about demand. The company has laid out the scope of its accounting findings, flagged material weaknesses, and set expectations for a down year in 2026. With profitability showing heightened sensitivity to mix and estimates, investors are likely to focus on execution and consistency. ICON currently carries a Zacks Rank #5 (Strong Sell). ICON’s Audit Committee review concluded that improper adjustments were made to clinical trial services revenue from third-quarter 2023 through fourth-quarter 2024. The issue primarily impacted the timing of revenue recognition, rather than the underlying business activity. The company disclosed the findings resulted in an overstatement of full-year revenue of $65 million in 2023 and $93 million in 2024. Beyond the revenue timing, the review also cited errors tied to cost-to-complete estimates, realizable value assessments, and certain manual adjustments that extended into 2025. In the past year, ICLR shares have surged 9.9% against the industry’s 3.2% decline. Image Source: Zacks Investment Research For investors, the timing element matters because it goes to the reliability of reported trend lines. When revenue is shifted across periods, it can distort growth comparisons, backlog conversion assumptions, and margin expectations that are built from quarterly patterns. Alongside the investigation findings, ICON identified material weaknesses in internal controls over financial reporting. The company cited gaps in both entity-level controls and controls over revenues and related accounts, which raises the bar for proving that the process is now repeatable and durable. Management is implementing a remediation plan that includes organizational changes, revised policies and procedures, additional training, and tighter controls over manual adjustments. The direction is clear: reduce discretion, improve oversight, and standardize how revenue-related judgments are made and reviewed. The confidence overhang is the timeline. Management has signaled that fully embedding remediation across 2026 remains a key risk for investor confidence, which can keep valuation and sentiment capped even if operating metrics begin to stabilize. Fourth-quarter 2025 results highlighted how quickly profitability can swing when mix and estimates move to...

A month has gone by since the last earnings report for TransMedics (TMDX). Shares have lost about 4.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is TransMedics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers. TransMedics delivered earnings per share of 30 cents in the first quarter of 2026, down 59.5% year over year. The figure missed the Zacks Consensus Estimate by 51.6%. TransMedics registered revenues of $173.9 million in the first quarter, up 21% year over year. The figure fell short of the Zacks Consensus Estimate by 1%. Per management, the year-over-year rise was driven by the increased utilization of the Organ Care System ("OCS"), primarily in Liver and Heart through the National OCS Program ("NOP"), as well as additional revenues generated by TransMedics logistics services. During the reported quarter, TMDX was able to cover 82% of its NOP missions requiring air transport compared with 78% in the first quarter of 2025. TMDX derives revenues via two sources: Net product revenues and Service revenues. In the first quarter of 2026, Net product revenues totaled $108 million, up 22% year over year. Growth was driven by continued strong liver performance and modest growth in the heart. Service revenues totaled $66 million, up 19% year over year, driven primarily by logistics revenues, supported by increased utilization of the TransMedics aviation fleet. Transplant Logistics’ services revenues for first-quarter 2026 were $32 million, up 22% year over year. This resulted from the continued expansion and strong utilization of TransMedics’ aviation fleet. In the quarter under review, TransMedics’ gross profit increased 14.7% year over year to $101.2 million. The gross margin contracted 331 basis points (bps) to 58%. Selling, general and administrative expenses rose 44.4% year over year to $62.9 million. Research, development and clinical trials expenses surged 45% year over year to $24.9 million. Total operating expenses of $87.9 million increased 44.5% year over year. Adjusted operating profit totaled $18.1 million, reflecting a downtick of 39.2% from the prior-year quarter. The adjusted operating margin in the first...

WALTHAM, Mass., May 20, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260520690669/en/ Contacts Media Contact Information:Sandy PoundThermo Fisher ScientificPhone: 781-622-1223E-mail: [email protected] Investor Contact Information:Rafael TejadaThermo Fisher ScientificPhone: 781-622-1356E-mail: [email protected]

Corning (GLW) reported Q1 2026 core sales of $4.35 billion, representing an 18% year-over-year increase. The core insight hiding beneath this headline beat is how entirely the AI-driven acceleration is offsetting the more modest growth currently seen in the company's traditional Glass Innovations segment. Photo by Bru-nO on Pixabay The Optical Communications segment surged 36% year-over-year to $1.8 billion, driven by the structural demand for high-density AI data center architectures. The company secured a $6 billion multi-year agreement with Meta Platforms (META) alongside two similarly sized hyperscaler deals in Q1. Furthermore, the Solar segment recorded 80% year-over-year growth. This combined secular strength expanded core gross margins by 120 basis points to 39.1% and operating margins by 220 basis points to 20.2%. See how Corning's growth and margins compare to those of its peers, including Thermo Fisher Scientific (TMO) and Danaher (DHR). Corning's core EPS rose 30% to $0.70, and management guided Q2 2026 sales to $4.6 billion. The AI infrastructure thesis is materializing exactly as projected. However, the Glass Innovations segment, which accounts for 32% of total revenue, stalled at just 1% year-over-year growth in Q1. Industry forecasts project global smartphone shipments will decline between 7% and 15% in 2026 due to component shortages and rising costs. A double-digit unit contraction will directly pressure high-margin Gorilla Glass volumes. Current market sentiment appears focused on the Optical surge, potentially underestimating the impact of near-term cyclical headwinds in mobile. Crucially, the market has already aggressively priced in this structural shift. Corning currently trades at 48 times its forward expected adjusted earnings. This is a severe expansion from its three-year average P/E multiple of approximately 21x. See how Corning's stock valuation compares with its peers. Investors are valuing a capital-intensive, cyclical materials manufacturer at a premium typically reserved for asset-light technology companies. The fundamental asymmetry has deteriorated, narrowing the margin of safety for investors entering at these levels. The transition of Corning into a primary AI infrastructure enabler is verified by the Q1 data, but the current valuation demands flawless execution. If the optical segment growth normalizes below 25% or the sm...

This article first appeared on GuruFocus. Revenue: Grew 6% to $11.01 billion in Q1. Adjusted Operating Income: Increased 6% to $2.4 billion. Adjusted Operating Margin: 21.8% for Q1. Adjusted EPS: Grew 6% to $5.44 per share. GAAP EPS: Increased 11% to $4.43. Organic Revenue Growth: 1% in Q1. Free Cash Flow: $830 million after $370 million of net capital expenditures. Share Buybacks: $3 billion repurchased in Q1. Dividend Increase: 10% increase in dividends. 2026 Revenue Guidance: Raised to $47.3 billion to $48.1 billion. 2026 Adjusted EPS Guidance: Raised to $24.64 to $25.12. Life Sciences Solutions Revenue: Increased 13%, with 1% organic growth. Analytical Instruments Revenue: Flat, with a 2% decrease in organic revenue. Specialty Diagnostics Revenue: Declined 1%, with a 3% decline in organic revenue. Laboratory Products and Biopharma Services Revenue: Increased 7%, with 4% organic growth. Warning! GuruFocus has detected 5 Warning Signs with TMO. Is TMO fairly valued? Test your thesis with our free DCF calculator. Release Date: April 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Thermo Fisher Scientific Inc (NYSE:TMO) reported a 6% increase in revenue for Q1 2026, reaching $11.01 billion. The company completed the acquisition of Clario, which added $30 million in revenue and $0.01 to adjusted EPS for the quarter. Thermo Fisher Scientific Inc (NYSE:TMO) raised its full-year revenue guidance to a range of $47.3 billion to $48.1 billion, reflecting 6% to 8% growth over 2025. The company launched several new technologies, including the Thermo Scientific Glacios 3 Cryo-TEM and the Thermo Scientific TSQ Certis mass spectrometer, enhancing its industry leadership. Thermo Fisher Scientific Inc (NYSE:TMO) repurchased $3 billion of shares and increased its dividend by 10% during the quarter, demonstrating strong capital return to shareholders. Revenue in the academic and government sector declined due to muted macro conditions in the US and China. The diagnostics and healthcare segment saw a mid-single-digit revenue decline, partly due to a weaker respiratory season. The Analytical Instruments segment experienced a 2% decrease in organic revenue, impacted by lower demand from academic and government customers. The company anticipates modest inflationary pressures due to the conflict in the Middle East, wh...